MedTrace Logo

Prophylaxis for COVID-19: Ivermectin in Close Contacts of COVID-19 Cases (IVERNEX-TUC)

NCT04894721 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 172

Last updated 2021-12-07

No results posted yet for this study

Summary

Randomized controlled clinical trial on using oral ivermectin in COVID-19 prophylaxis supplying the drug to close contacts of confirmed cases.

Conditions

  • Covid19

Interventions

DRUG

Ivermectin

0,6mg/kg of weight orally on days 1 and 7

OTHER

Placebo

A substance with similar physical characteristics as ivermectin, without the active drug ingredient

Sponsors & Collaborators

  • Ministry of Public Health, Argentina

    lead OTHER_GOV

Principal Investigators

  • Rossana Chahla, Ph. D · Ministry of Public Health, Tucumán, Argentina

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2021-09-30
Completion
2021-10-01

Countries

  • Argentina

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04894721 on ClinicalTrials.gov